CLNN Clene Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CLNN

Price (delayed)

$4.29

Market cap

$55.12M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.5

Enterprise value

$67.74M

?
Relative Growth: Rel. Growth: 15
Relative Strength: Rel. Strength: 14
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 14

Clene Inc., (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function ...

Highlights
CLNN's quick ratio has soared by 126% from the previous quarter and by 107% YoY
The revenue rose by 47% QoQ but it fell by 31% YoY
The gross profit has contracted by 40% YoY but it has grown by 24% from the previous quarter
The equity has plunged by 190% YoY and by 32% from the previous quarter
The net income is down by 33% YoY and by 18% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://clene.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CLNN

CLNN stock price

How has the Clene stock price performed over time
Intraday
-2.05%
1 week
11.14%
1 month
-0.69%
1 year
-29.9%
YTD
-26.92%
QTD
-30.3%

Financial performance

How have Clene's revenue and profit performed over time
Revenue
$197,000
Gross profit
$138,000
Operating income
-$20.55M
Net income
-$39.52M
Gross margin
70.1%
Net margin
-20,059.9%
The company's net margin has shrunk by 93% YoY but it rose by 20% QoQ
The revenue rose by 47% QoQ but it fell by 31% YoY
The gross profit has contracted by 40% YoY but it has grown by 24% from the previous quarter
Clene's operating margin has increased by 34% from the previous quarter but it has decreased by 13% YoY

Price vs fundamentals

How does CLNN's price correlate with its fundamentals

Growth

What is Clene's growth rate over time

Valuation

What is Clene stock price valuation
P/E
N/A
P/B
N/A
P/S
269.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
343.83
CLNN's EPS is down by 9% since the previous quarter but it is up by 7% year-on-year
The equity has plunged by 190% YoY and by 32% from the previous quarter
The revenue rose by 47% QoQ but it fell by 31% YoY
The stock's price to sales (P/S) is 21% less than its last 4 quarters average of 348.6 but 12% more than its 5-year quarterly average of 245.4

Efficiency

How efficient is Clene business performance
CLNN's return on sales has dropped by 98% year-on-year but it is up by 19% since the previous quarter
The ROA has plunged by 66% YoY and by 17% from the previous quarter
Clene's return on invested capital has decreased by 17% QoQ and by 15% YoY

Dividends

What is CLNN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLNN.

Financial health

How did Clene financials performed over time
The total assets is 52% smaller than the total liabilities
CLNN's quick ratio has soared by 126% from the previous quarter and by 107% YoY
The company's current ratio has surged by 94% YoY and by 58% QoQ
The company's debt is 190% higher than its equity
The equity has plunged by 190% YoY and by 32% from the previous quarter
Clene's debt to equity has surged by 63% YoY and by 23% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.